News
The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...
The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...
Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...
Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
Moderna's Spikevax vaccine has been fully approved for children with high-risk conditions, the first vaccine to do so.
StockStory.org on MSN1d
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA)As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...
The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...
The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, ...
The Food and Drug Administration (FDA) granted full approval on Thursday to Moderna’s COVID-19 vaccine for children, making it the first COVID shot for kids aged 6 months to 11 years old that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results